TAKEDA PHARMACEUTICAL CO LTD

Listed Company
TAKCIK 0001395064NYSELarge AcceleratedPharmaceutical PreparationsJP
Period
FY 2026
Revenue
Net Income
$-152.13B
Total Assets
$15.51T
Equity
Shares Out
1.56B
Op. Cash Flow
+ 13F Filer
TAK$17.16+16.46% · past yearDBEQ Basic
Daily closing prices

Business

Takeda Pharmaceutical Co Ltd is a global R&D-driven biopharmaceutical company that discovers and delivers treatments across gastrointestinal and inflammation, neuroscience, oncology, plasma-derived therapies, and vaccines. Principal marketed products include ENTYVIO for inflammatory bowel disease, TAKHZYRO for hereditary angioedema, immunoglobulin therapies, and oncology medicines such as ADCETRIS and NINLARO. The company operates through regional business units in the U.S., Japan, Europe, and emerging markets including China, with a geographically diversified manufacturing and research footprint.

Summary from 20-F filed 2026-06-17

Financials

Latest annual snapshot (FY2026, period end 2026-03-31). Full statement history unavailable for this entity.

Revenue
Net income$-152.13B
Total assets$15.51T
Total liabilities$8.08T
Stockholders' equity
Operating cash flow

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Holdings (13F)

Portfolio as of 2025-09-30 · 9 positions

Reported AUM
$16.37M
Holdings
9
Top sector
$16.37M

Top sectors

SectorValue% of portfolio
Uncategorized$16.37M100.0%

Top holdings

IssuerTickerSharesValue%
Ovid Therapeutics, Inc.5.75M$7.47M45.7%
Equillium, Inc.1.82M$2.61M15.9%
Ovid Therapeutics, Inc.1.78M$2.32M14.2%
Xilio Therapeutics, Inc. (formerly Akrevia Therapeutics)1.48M$1.24M7.6%
Shattuck Labs, Inc.515.6K$1.23M7.5%
Lyell Immunopharma, Inc.54.9K$891.0K5.4%
American Well Corporation77.7K$478.0K2.9%
Rani Therapeutics Holdings, Inc.203.2K$101.0K0.6%
Standard Biotools, Inc.16.5K$21.0K0.1%

Frequently asked questions

What is TAKEDA PHARMACEUTICAL CO LTD's CIK number?

TAKEDA PHARMACEUTICAL CO LTD's SEC CIK number is 0001395064 (1395064). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find TAKEDA PHARMACEUTICAL CO LTD's SEC filings?

All of TAKEDA PHARMACEUTICAL CO LTD's EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

Look up any company's CIK number →